Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002278 · ClinicalTrials.gov registry record · NA

A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS

A NA study of HIV Infections and Cryptosporidiosis, sponsored by Janssen.

Completed
Registry status
NA
Development phase
3
Study locations

NCT00002278: Completed NA study of HIV Infections and Cryptosporidiosis, sponsored by Janssen.

NCT00002278 is a NA study of HIV Infections and Cryptosporidiosis that has completed, run by Janssen. The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002278, a NA study of HIV Infections and Cryptosporidiosis, has completed, sponsored by Janssen.

COMPLETED
Registry status
NA
Development phase
3
Study locations

Study Summary

To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this protocol.

Conditions Studied

HIV Infections Cryptosporidiosis

Interventions

  • DRUG Diclazuril

Study Locations (3)

New York

  • Bellevue Hosp / New York Univ Med Ctr - New York
  • Cornell Univ Med Ctr - New York
  • Saint Luke's - Roosevelt Hosp Ctr - New York

Trial Details

FieldValue
Phase NA
Janssen

10 total trials

What the finished NCT00002278 record still lists

NCT00002278 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Diclazuril is the first listed.

NCT00002278 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00002278 about?

NCT00002278 is a clinical study titled "A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS". To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and w...

What is the current status of trial NCT00002278?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002278 study?

This clinical trial studies the following conditions: HIV Infections, Cryptosporidiosis.

What interventions are being tested in trial NCT00002278?

The interventions under investigation include: Diclazuril (DRUG).

Who is sponsoring clinical trial NCT00002278?

This trial is sponsored by Janssen, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002278 being conducted?

This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002278, the US trial registry maintained by the National Library of Medicine. NCT00002278 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.